Full year report 2017
“We are fully dedicated to achieving approvals for CAM2038 in Europe, Australia and the US during 2018, and the launch preparations for this much-needed treatment of opioid dependence are progressing according to plan.”Business highlights fourth quarter 2017 · Recommendation of approval of CAM2038 NDA by the FDA Advisory Committees. · Acceptance of CAM2038 MAA for review by the Australian TGA. · All patients enrolled in Phase 3 efficacy and long-term safety extension study of CAM2038 in chronic pain · Positive Phase 1 results after repeat dosing of weekly setmelanotide